Pegcetacoplan is a synthetic cyclic peptide conjugated to a polyethylene glycol (PEG) polymer that inhibits the complement cascade centrally at C3. Apellis Pharmaceuticals announced positive topline ...
When drug development and the immune system collide we get CAR-T, checkpoint inhibitors, oncolytic vaccines, monoclonal antibodies and more. These fields have produced many therapies and garnered a ...
October 16, 2012 (Boston, Massachusetts) — Eculizumab, a humanized monoclonal antibody that inhibits cleavage of complement component C5 to active forms, significantly reduced the annual rate of ...
"Atypical Hemolytic Uremic Syndrome Pipeline"Following the success of terminal complement inhibitors like eculizumab and ravulizumab, the therapeutic focus in 2025 has shifted towards developing ...
Please provide your email address to receive an email when new articles are posted on . Paroxysmal nocturnal hemoglobinuria is a rare disorder that has fascinated clinicians and scientists for more ...
A recent study found that thrombotic events occurred in 3 out of 26 patients who received eculizumab, compared with 3 out of 13 who did not receive the therapy. Some symptoms, including abdominal ...
Please provide your email address to receive an email when new articles are posted on . The monoclonal antibody eculizumab has received accelerated approval from the FDA for the treatment of pediatric ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback